Evolution of Strain Coverage by the Multicomponent Meningococcal Serogroup B Vaccine (4CMenB) in France

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2021 Dec 3

PMID 34856875

Citations 6

Authors

Eva Hong

Aude Terrade

Alessandro Muzzi

Rosita De Paola

Giuseppe Boccadifuoco

Rita La Gaetana

Ala-Eddine Deghmane

Mariagrazia Pizza

Laura Serino

Muhamed-Kheir Taha

Affiliations

Soon will be listed here.

Abstract

The 4CMenB, a protein-based vaccine, was licensed in Europe in 2013 against invasive meningococcal disease caused by serogroup B and is currently implemented in several countries although according to different national strategies. Isolate coverage estimation is required as vaccine-targeted antigens may vary among isolates over time. Several phenotypic and genotypic methods have been developed to predict strain coverage by scoring the expression and cross-reactivity of vaccine antigens using the Meningococcal Antigen Typing system (MATS), by the genetic correlation of alleles encoding these antigens and MATS expression data (gMATS) and by the Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR). We applied these approaches on meningococcal B isolates in France and compared two epidemiological years, 2013-2014 and 2018-2019. A strong correlation was observed between MATS data that were generated for the year 2013-2014 and the gMATS data extracted from whole genome sequencing. gMATS and MenDeVAR were next used to compare the two years. Using gMATS, the overall coverage was 77.2% (lower limit (LL)-upper limit (UL) 66.7-87.7) and 70.7% (LL-UL 61.5-80.0) for the two years, respectively. The reduction in coverage between the two years is mainly driven by the reduction of alleles exactly matching the vaccine antigens. A high number of unpredictable isolates was observed using the MenDeVAR and was due to lack of MATS information for new or rare alleles in particular for the year 2018-2019. Our data underline the need of continuous surveillance of strain coverage and the importance of generating phenotypic MATS data to update the genetic approaches of prediction.

Citing Articles

Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 isolates causing invasive meningococcal disease in Argentina in 2010-2014.

Efron A, Brozzi A, Biolchi A, Bodini M, Giuliani M, Guidotti S Hum Vaccin Immunother. 2024; 20(1):2378537.

PMID: 39037011 PMC: 11789736. DOI: 10.1080/21645515.2024.2378537.

4CMenB journey to the 10-year anniversary and beyond.

Abitbol V, Martinon-Torres F, Taha M, Nolan T, Muzzi A, Bambini S Hum Vaccin Immunother. 2024; 20(1):2357924.

PMID: 38976659 PMC: 11232649. DOI: 10.1080/21645515.2024.2357924.

Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020.

Muzzi A, Lu M, Mori E, Biolchi A, Fu T, Serino L mSphere. 2024; 9(6):e0022024.

PMID: 38752729 PMC: 11338074. DOI: 10.1128/msphere.00220-24.

Molecular characterization of invasive isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage.

Sereikaite E, Plepyte R, Petrutiene A, Stravinskiene D, Kucinskaite-Kodze I, Gegzna V Front Cell Infect Microbiol. 2023; 13:1136211.

PMID: 36875527 PMC: 9975601. DOI: 10.3389/fcimb.2023.1136211.

Epidemiology and Clinical Burden of Meningococcal Disease in France: Scoping Review.

Baloche A, Dussart C, Bedouch P, Carrouel F, Mick G J Clin Med. 2023; 12(3).

PMID: 36769498 PMC: 9917955. DOI: 10.3390/jcm12030849.

References

Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J . Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013; 31(43):4968-74. DOI: 10.1016/j.vaccine.2013.08.006. View

Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C . Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010; 107(45):19490-5. PMC: 2984153. DOI: 10.1073/pnas.1013758107. View

Borrow R, Taha M, Giuliani M, Pizza M, Banzhoff A, Bekkat-Berkani R . Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence. J Infect. 2020; 81(6):862-872. DOI: 10.1016/j.jinf.2020.07.034. View

Rodrigues C, Jolley K, Smith A, Cameron J, Feavers I, Maiden M . Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool That Exploits Genomic Data in Public Health and Clinical Microbiology Applications. J Clin Microbiol. 2020; 59(1). PMC: 7771438. DOI: 10.1128/JCM.02161-20. View

Vogel U, Taha M, Vazquez J, Findlow J, Claus H, Stefanelli P . Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013; 13(5):416-25. DOI: 10.1016/S1473-3099(13)70006-9. View

Taha M, Gaudelus J, Deghmane A, Caron F . Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries. Hum Vaccin Immunother. 2020; 16(10):2518-2523. PMC: 7644201. DOI: 10.1080/21645515.2020.1729030. View

Ladhani S, Andrews N, Parikh S, Campbell H, White J, Edelstein M . Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. N Engl J Med. 2020; 382(4):309-317. DOI: 10.1056/NEJMoa1901229. View

Acevedo R, Bai X, Borrow R, Caugant D, Carlos J, Ceyhan M . The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2018; 18(1):15-30. DOI: 10.1080/14760584.2019.1557520. View

Parikh S, Campbell H, Bettinger J, Harrison L, Marshall H, Martinon-Torres F . The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020; 81(4):483-498. DOI: 10.1016/j.jinf.2020.05.079. View

10.

Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D . Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019; 37(7):991-1000. DOI: 10.1016/j.vaccine.2018.12.061. View

11.

Jolley K, Chan M, Maiden M . mlstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics. 2004; 5:86. PMC: 459212. DOI: 10.1186/1471-2105-5-86. View

12.

Santolaya M, ORyan M, Valenzuela M, Prado V, Vergara R, Munoz A . Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012; 379(9816):617-24. DOI: 10.1016/S0140-6736(11)61713-3. View

13.

Caron F, Parent du Chatelet I, Leroy J, Ruckly C, Blanchard M, Bohic N . From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011; 11(6):455-63. DOI: 10.1016/S1473-3099(11)70027-5. View

14.

Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, Orlandi L . Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol. 2014; 14:111. PMC: 4018652. DOI: 10.1186/1471-2180-14-111. View

15.

Plikaytis B, Stella M, Boccadifuoco G, DeTora L, Agnusdei M, Santini L . Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012; 19(10):1609-17. PMC: 3485892. DOI: 10.1128/CVI.00202-12. View

16.

Jolley K, Maiden M . Automated extraction of typing information for bacterial pathogens from whole genome sequence data: Neisseria meningitidis as an exemplar. Euro Surveill. 2013; 18(4):20379. PMC: 3977036. DOI: 10.2807/ese.18.04.20379-en. View

17.

Parent du Chatelet I, Deghmane A, Antona D, Hong E, Fonteneau L, Taha M . Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015. J Infect. 2017; 74(6):564-574. DOI: 10.1016/j.jinf.2017.02.011. View

18.

Hong E, Bakhalek Y, Taha M . Identification of Neisseria meningitidis by MALDI-TOF MS may not be reliable. Clin Microbiol Infect. 2018; 25(6):717-722. DOI: 10.1016/j.cmi.2018.09.015. View

19.

Deghmane A, Haeghebaert S, Hong E, Jousset A, Barret A, Taha M . Emergence of new genetic lineage, ST-9316, of Neisseria meningitidis group W in Hauts-de-France region, France 2013-2018. J Infect. 2020; 80(5):519-526. DOI: 10.1016/j.jinf.2020.01.020. View

20.

Tozer S, Smith H, Whiley D, Borrow R, Boccadifuoco G, Medini D . High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS. Hum Vaccin Immunother. 2021; 17(9):3230-3238. PMC: 8381844. DOI: 10.1080/21645515.2021.1904758. View